
The deal includes an approved treatment for acromegaly and other pipeline candidates

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...

With rapid growth comes growing pains...

Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

Amended agreement sees Vertex take control of gene therapy programme

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

The drug will immediately become available to thousands of cystic fibrosis patients

Patients had no side effects following CRISPR treatment